DNER and acute myeloid leukemia: A Genentech patent also investigated the effects of SGC-CBP30 and I-CBP112 BET inhibitor resistant cells.62 The BET inhibitor resistant cells were generated by treating acute myeloid leukemia cells (NOMO-1) with increasing concentrations of a BET inhibitor.